This protocol requires a physician consultation and prescription prior to fulfillment.

Tirzepatide is a once-weekly injectable medication that acts as a dual GIP and GLP-1 receptor agonist. It regulates insulin secretion, slows gastric emptying, and reduces appetite. Clinical studies show that Tirzepatide significantly improves blood sugar control and supports substantial, sustainable weight loss when used under medical supervision.

Benefits

Promotes significant and sustainable weight loss
Improves blood glucose regulation and insulin sensitivity
Reduces appetite and food cravings
Supports cardiovascular and metabolic health

Estimated duration: 12 weeks following standard titration: 2.5mg weekly for weeks 1-4, 5mg weekly for weeks 5-8, 7.5mg weekly for weeks 9-12

Estimated durations are based on common titration approaches and may vary depending on individual dosing and provider guidance.

https://patients.outfitmd.com/portal/